AU2005267111B2 - Enriched antibody for detecting mycobacterial infection, methods of use and diagnostic test employing same - Google Patents
Enriched antibody for detecting mycobacterial infection, methods of use and diagnostic test employing same Download PDFInfo
- Publication number
- AU2005267111B2 AU2005267111B2 AU2005267111A AU2005267111A AU2005267111B2 AU 2005267111 B2 AU2005267111 B2 AU 2005267111B2 AU 2005267111 A AU2005267111 A AU 2005267111A AU 2005267111 A AU2005267111 A AU 2005267111A AU 2005267111 B2 AU2005267111 B2 AU 2005267111B2
- Authority
- AU
- Australia
- Prior art keywords
- lam
- antigen
- sample
- polyclonal antibody
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims description 74
- 206010062207 Mycobacterial infection Diseases 0.000 title claims description 21
- 208000027531 mycobacterial infectious disease Diseases 0.000 title claims description 21
- 238000002405 diagnostic procedure Methods 0.000 title description 11
- 239000000427 antigen Substances 0.000 claims description 82
- 102000036639 antigens Human genes 0.000 claims description 82
- 108091007433 antigens Proteins 0.000 claims description 82
- 238000002965 ELISA Methods 0.000 claims description 60
- 210000002700 urine Anatomy 0.000 claims description 57
- 238000012360 testing method Methods 0.000 claims description 47
- 201000008827 tuberculosis Diseases 0.000 claims description 41
- 206010036790 Productive cough Diseases 0.000 claims description 33
- 208000024794 sputum Diseases 0.000 claims description 33
- 210000003802 sputum Anatomy 0.000 claims description 32
- 150000004676 glycans Chemical class 0.000 claims description 27
- 229920001282 polysaccharide Polymers 0.000 claims description 25
- 239000005017 polysaccharide Substances 0.000 claims description 25
- 238000003556 assay Methods 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 19
- 241000872931 Myoporum sandwicense Species 0.000 claims description 17
- 238000007254 oxidation reaction Methods 0.000 claims description 15
- 230000000890 antigenic effect Effects 0.000 claims description 14
- 239000011159 matrix material Substances 0.000 claims description 14
- 241000186359 Mycobacterium Species 0.000 claims description 13
- 230000002685 pulmonary effect Effects 0.000 claims description 12
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical group [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 12
- 230000003647 oxidation Effects 0.000 claims description 11
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 6
- 230000000717 retained effect Effects 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000007800 oxidant agent Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000007717 exclusion Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 230000001355 anti-mycobacterial effect Effects 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 83
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 36
- 239000002953 phosphate buffered saline Substances 0.000 description 36
- 230000035945 sensitivity Effects 0.000 description 30
- 239000011521 glass Substances 0.000 description 24
- 239000000523 sample Substances 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 22
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 21
- 238000001514 detection method Methods 0.000 description 21
- 238000003745 diagnosis Methods 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 17
- 239000000872 buffer Substances 0.000 description 16
- 239000006228 supernatant Substances 0.000 description 15
- 238000000386 microscopy Methods 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 229920002684 Sepharose Polymers 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 12
- 238000010168 coupling process Methods 0.000 description 12
- 238000003018 immunoassay Methods 0.000 description 12
- 239000003446 ligand Substances 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 11
- 230000008878 coupling Effects 0.000 description 11
- 238000005859 coupling reaction Methods 0.000 description 11
- 238000000502 dialysis Methods 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- 238000003260 vortexing Methods 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 9
- 239000008367 deionised water Substances 0.000 description 9
- 229910021641 deionized water Inorganic materials 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- 208000036981 active tuberculosis Diseases 0.000 description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 6
- 230000021615 conjugation Effects 0.000 description 6
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 229920005654 Sephadex Polymers 0.000 description 5
- 239000012507 Sephadex™ Substances 0.000 description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- 238000001994 activation Methods 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000011888 foil Substances 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- IMIVWAUMTAIVPJ-XUXIUFHCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-azaniumyl-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-4-methylpentanoate Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CC(C)C IMIVWAUMTAIVPJ-XUXIUFHCSA-N 0.000 description 4
- 206010027259 Meningitis tuberculous Diseases 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 208000001223 meningeal tuberculosis Diseases 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102100028626 4-hydroxyphenylpyruvate dioxygenase Human genes 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000003322 Coinfection Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229920000057 Mannan Polymers 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000022971 Tuberculous meningitis Diseases 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000002601 radiography Methods 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 238000009589 serological test Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 229960004249 sodium acetate Drugs 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 241000304886 Bacilli Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000186366 Mycobacterium bovis Species 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- -1 mannose oligosaccharides Chemical class 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 239000005297 pyrex Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010056377 Bone tuberculosis Diseases 0.000 description 1
- 101100399480 Caenorhabditis elegans lmn-1 gene Proteins 0.000 description 1
- FDEQQCOTLPPCAO-UHFFFAOYSA-N Cl.OC(O)=O Chemical compound Cl.OC(O)=O FDEQQCOTLPPCAO-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000006674 extrapulmonary tuberculosis Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- UMHAZRHZAQYINK-UCLGWUJRSA-N hrp-5 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CC1N=CN=C1)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)OC(=O)CC[C@H](NC(=O)[C@H](CC1N=CN=C1)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CC1N=CN=C1)C(=O)OC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC1N=CN=C1)NC(=O)[C@@H](N)CO)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(O)=O)C1C=NC=N1 UMHAZRHZAQYINK-UCLGWUJRSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000016178 immune complex formation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58941904P | 2004-07-20 | 2004-07-20 | |
| US60/589,419 | 2004-07-20 | ||
| PCT/US2005/025875 WO2006012413A1 (en) | 2004-07-20 | 2005-07-20 | Enriched antibody for detecting mycobacterial infection, methods of use and diagnostic test employing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2005267111A1 AU2005267111A1 (en) | 2006-02-02 |
| AU2005267111B2 true AU2005267111B2 (en) | 2011-03-03 |
Family
ID=35432542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005267111A Ceased AU2005267111B2 (en) | 2004-07-20 | 2005-07-20 | Enriched antibody for detecting mycobacterial infection, methods of use and diagnostic test employing same |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US7335480B2 (enExample) |
| EP (1) | EP1771475B1 (enExample) |
| JP (1) | JP4948402B2 (enExample) |
| CN (1) | CN101014622B (enExample) |
| AP (1) | AP2316A (enExample) |
| AT (1) | ATE500272T1 (enExample) |
| AU (1) | AU2005267111B2 (enExample) |
| BR (1) | BRPI0513596B8 (enExample) |
| CA (1) | CA2574432C (enExample) |
| DE (1) | DE602005026665D1 (enExample) |
| EA (1) | EA013228B1 (enExample) |
| MX (1) | MX2007000916A (enExample) |
| UA (1) | UA92721C2 (enExample) |
| WO (1) | WO2006012413A1 (enExample) |
| ZA (1) | ZA200700525B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006012413A1 (en) | 2004-07-20 | 2006-02-02 | Chemogen, Inc. | Enriched antibody for detecting mycobacterial infection, methods of use and diagnostic test employing same |
| WO2008067497A2 (en) * | 2006-11-29 | 2008-06-05 | Chemogen, Inc. | Enriched antibody for detecting mycobacterial infection, methods of use and diagnostic test employing same |
| US20100317037A1 (en) * | 2009-06-16 | 2010-12-16 | Sina Biotechnical Co. | Detection of Mycobacterium Tuberculosis Bacilli |
| EP2668207A4 (en) | 2011-01-24 | 2015-06-10 | Univ Singapore | MANNOSE-CAPTURED LIPOARABINOMANANE ANTIGEN-BINDING PROTEINS OBTAINED FROM ILLNESSIFYING MYCOBACTERIES |
| US10729771B2 (en) | 2016-02-10 | 2020-08-04 | Rutgers, The State University Of New Jersey | Anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of Mycobacterium tuberculosis infections |
| US10837962B2 (en) | 2017-12-20 | 2020-11-17 | General Electric Company | Method and associated device for rapid detection of target biomolecules with enhanced sensitivity |
| US10830760B2 (en) | 2017-12-20 | 2020-11-10 | General Electric Company | Device for rapid detection of tuberculosis-lipoarabinomannan (TB-LAM) with enhanced sensitivity |
| US20210302424A1 (en) * | 2018-07-19 | 2021-09-30 | Rutgers, The State University Of New Jersey | Methods for dual detection and differentiation of infection by mycobacterium tuberculosis complex and nontuberculous mycobacteria |
| CN112639472A (zh) | 2018-08-31 | 2021-04-09 | 富士胶片株式会社 | 免疫层析试剂盒及结核菌的检测方法 |
| CN111234026A (zh) * | 2020-02-21 | 2020-06-05 | 首都医科大学附属北京胸科医院 | 特异性结合脂阿拉伯甘露聚糖的单克隆抗体及其在分枝杆菌检测中的应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992014155A1 (en) * | 1991-02-12 | 1992-08-20 | Dynagen, Inc. | Monoclonal antibodies directed towards mycobacterial antigens |
| WO1997034119A1 (en) * | 1996-03-11 | 1997-09-18 | Royal Ordnance Public Limited Company | Howitzer anchor spade |
| WO2001064237A1 (en) * | 2000-03-01 | 2001-09-07 | Binax, Inc. | Method for detecting the presence of target bacteria or a target component carbohydrate antigen thereof |
| US20020034763A1 (en) * | 1997-06-04 | 2002-03-21 | Amster, Rothstein & Ebenstein | Monoclonal antibodies to mycobacterium tuberculosis and a modified elisa assay |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214789B1 (en) | 1993-03-12 | 2001-04-10 | Xoma Corporation | Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products |
| US5756327A (en) | 1994-09-13 | 1998-05-26 | Cubist Pharmaceuticals, Inc. | Recombinant mycobacterial isoleucyl-tRNA synthetase genes, tester strains and assays |
| AU1750197A (en) | 1996-01-17 | 1997-08-11 | Trustees Of Boston University | Mycobacterium antigens and methods for their detection |
| SE9600949D0 (sv) * | 1996-03-12 | 1996-03-12 | Stefan Svenson | Method of diagnosing a mycobacterial disease and immunoassay kit |
| US20040038201A1 (en) | 2002-01-22 | 2004-02-26 | Whitehead Institute For Biomedical Research | Diagnostic and therapeutic applications for biomarkers of infection |
| WO2006012413A1 (en) | 2004-07-20 | 2006-02-02 | Chemogen, Inc. | Enriched antibody for detecting mycobacterial infection, methods of use and diagnostic test employing same |
| WO2008067497A2 (en) | 2006-11-29 | 2008-06-05 | Chemogen, Inc. | Enriched antibody for detecting mycobacterial infection, methods of use and diagnostic test employing same |
-
2005
- 2005-07-20 WO PCT/US2005/025875 patent/WO2006012413A1/en not_active Ceased
- 2005-07-20 AT AT05791349T patent/ATE500272T1/de not_active IP Right Cessation
- 2005-07-20 AP AP2007003884A patent/AP2316A/xx active
- 2005-07-20 AU AU2005267111A patent/AU2005267111B2/en not_active Ceased
- 2005-07-20 CA CA2574432A patent/CA2574432C/en not_active Expired - Fee Related
- 2005-07-20 DE DE602005026665T patent/DE602005026665D1/de not_active Expired - Lifetime
- 2005-07-20 BR BRPI0513596A patent/BRPI0513596B8/pt not_active IP Right Cessation
- 2005-07-20 CN CN200580029939XA patent/CN101014622B/zh not_active Expired - Fee Related
- 2005-07-20 EP EP05791349A patent/EP1771475B1/en not_active Expired - Lifetime
- 2005-07-20 MX MX2007000916A patent/MX2007000916A/es active IP Right Grant
- 2005-07-20 US US11/186,933 patent/US7335480B2/en not_active Expired - Lifetime
- 2005-07-20 JP JP2007522751A patent/JP4948402B2/ja not_active Expired - Lifetime
- 2005-07-20 EA EA200700345A patent/EA013228B1/ru unknown
- 2005-07-20 UA UAA200701647A patent/UA92721C2/ru unknown
-
2007
- 2007-01-18 ZA ZA200700525A patent/ZA200700525B/xx unknown
- 2007-10-31 US US11/932,722 patent/US7615222B2/en not_active Expired - Lifetime
-
2009
- 2009-10-19 US US12/581,603 patent/US8057797B2/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992014155A1 (en) * | 1991-02-12 | 1992-08-20 | Dynagen, Inc. | Monoclonal antibodies directed towards mycobacterial antigens |
| WO1997034119A1 (en) * | 1996-03-11 | 1997-09-18 | Royal Ordnance Public Limited Company | Howitzer anchor spade |
| US20020034763A1 (en) * | 1997-06-04 | 2002-03-21 | Amster, Rothstein & Ebenstein | Monoclonal antibodies to mycobacterium tuberculosis and a modified elisa assay |
| WO2001064237A1 (en) * | 2000-03-01 | 2001-09-07 | Binax, Inc. | Method for detecting the presence of target bacteria or a target component carbohydrate antigen thereof |
Non-Patent Citations (1)
| Title |
|---|
| SCHWEBACH J R ET AL: "Expression of a Mycobacterium tuberculosis arabinomannan antigen in vitro and in vivo." INFECTION AND IMMUNITY. 2001; vol. 69(9):5671-5678 * |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0513596B1 (pt) | 2018-02-06 |
| EP1771475A1 (en) | 2007-04-11 |
| EA200700345A1 (ru) | 2007-08-31 |
| JP4948402B2 (ja) | 2012-06-06 |
| US20100210823A1 (en) | 2010-08-19 |
| UA92721C2 (ru) | 2010-12-10 |
| US8057797B2 (en) | 2011-11-15 |
| DE602005026665D1 (de) | 2011-04-14 |
| AP2316A (en) | 2011-11-04 |
| ZA200700525B (en) | 2008-09-25 |
| AU2005267111A1 (en) | 2006-02-02 |
| US7615222B2 (en) | 2009-11-10 |
| WO2006012413A1 (en) | 2006-02-02 |
| JP2008507544A (ja) | 2008-03-13 |
| US20080213806A1 (en) | 2008-09-04 |
| BRPI0513596B8 (pt) | 2021-07-27 |
| CN101014622B (zh) | 2011-12-28 |
| EA013228B1 (ru) | 2010-04-30 |
| AP2007003884A0 (en) | 2007-02-28 |
| CA2574432A1 (en) | 2006-02-02 |
| ATE500272T1 (de) | 2011-03-15 |
| CN101014622A (zh) | 2007-08-08 |
| EP1771475B1 (en) | 2011-03-02 |
| CA2574432C (en) | 2015-05-26 |
| MX2007000916A (es) | 2007-07-09 |
| US7335480B2 (en) | 2008-02-26 |
| BRPI0513596A (pt) | 2008-05-13 |
| US20060127406A1 (en) | 2006-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8057797B2 (en) | Method of preparing enriched antibodies for detecting mycobacterial infection | |
| EP1381864B1 (en) | Detection of candida | |
| WO2008073895A2 (en) | Methods and devices for testing saliva | |
| Tiwari et al. | Glycolipids of Mycobacterium tuberculosis strain H37Rv are potential serological markers for diagnosis of active tuberculosis | |
| Rajan et al. | Serodiagnosis of tuberculosis based on the analysis of the 65 kD heat shock protein of Mycobacterium tuberculosis | |
| WO2008067497A9 (en) | Enriched antibody for detecting mycobacterial infection, methods of use and diagnostic test employing same | |
| Stavri et al. | Rapid dot sputum and serum assay in pulmonary tuberculosis | |
| CN1866023B (zh) | 一种同步检测多种结核杆菌特异性分泌抗原的方法 | |
| EP2737316B1 (en) | A diagnostic kit for the detection of early acute leptospirosis | |
| HK1106780A (en) | Enriched antibody for detecting mycobacterial infection, methods of use and diagnostic test employing same | |
| KR100254414B1 (ko) | 항-결핵균 항체 및 나균 항원에 대한 항혈청을 포함하는 결핵균 항원 검출용 진단키트 | |
| EP1259249B1 (en) | Method for detecting the presence of target bacteria or a target component carbohydrate antigen thereof | |
| Deodhar et al. | Standardization of a dot blot immunoassay for antigen detection in cases of pulmonary tuberculosis & its evaluation with respect to the conventional techniques | |
| US20100317037A1 (en) | Detection of Mycobacterium Tuberculosis Bacilli | |
| Stavri et al. | Serodiagnosis of environmental mycobacterial infections | |
| JP2017132712A (ja) | モノクローナル抗体、検出方法、及び検出装置 | |
| JP2002372531A (ja) | 喀痰中の原因菌の消化断片を利用した呼吸器感染症の診断方法 | |
| JPH0726962B2 (ja) | 病原細菌が産生する毒素の簡易迅速かつ高感度検査法 | |
| Hassan et al. | The Utility of Homemade ELISA Based Outer Membrane Proteins (OMP) of Salmonella Typhi in Diagnosis of Chronic Typhoid Carrier | |
| Tiwari | Abréviations 20 | |
| JPWO2001081927A1 (ja) | ストレプトコッカス・ソブリヌスの検出方法及びそのための抗体 | |
| JP2002243742A (ja) | 抗酸菌症鑑別用試薬および鑑別方法 | |
| JPH0222295A (ja) | ポリミキシンアガロースリポ多糖抗原及びこれに関連する方法 | |
| JP2007300817A (ja) | 細菌の検出方法、検出用試薬及び検出用キット。 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |